CURIS, INC. DETERMINES TO OPT OUT OF CO-DEVELOPMENT OF BASAL CELL CARCINOMA DRUG CANDIDATE

Curis, Inc., a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, announced that pursuant to the terms of its 2003 collaboration agreement with Genentech it has elected to cease its participation in the co-development of the basal cell carcinoma drug candidate for which the parties had previously announced they were halting enrollment in the Phase I clinical trial and had made a decision not to move forward with the molecule in its current formulation.
BioSpace